Comprehensive Clinical, Biochemical and Genetic Screening Reveals Four Distinct Genotypes As Underlying Variable Manifestation of Gaucher Disease in a Single Family

Overview

Journal Mol Genet Metab Rep

Specialty Endocrinology

Date 2019 Nov 12

PMID 31709146

Citations 5

Authors

P Cullufi

M Tabaku

C Beetz

S Tomori

V Velmishi

A Gjikopulli

P Bauer

S Wirth

A Rolfs

Affiliations

Soon will be listed here.

Abstract

Gaucher disease (GD) is a lysosomal storage disorder that is associated with bi-allelic pathogenic variants in . Its wide clinical spectrum, ranging from mild organomegaly to significant skeletal and neurological involvement, is partially explained by genotype-phenotype correlations. We present a family, in which all members over two generations presented with at least splenomegaly. Comprehensive clinical, biochemical and genetic workup was required to diagnose GD, which is caused by as many as four distinct genotypes.

Citing Articles

Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.

Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt E, Laabs B Brain. 2024; 147(8):2652-2667.

PMID: 39087914 PMC: 11292909. DOI: 10.1093/brain/awae188.

A rare homozygous p.Arg87Trp variant of the gene in Gaucher disease: A case report.

Jilani H, Hsoumi F, Rejeb I, Elaribi Y, Hizem S, Sebai M Clin Case Rep. 2022; 10(5):e05846.

PMID: 35592045 PMC: 9097371. DOI: 10.1002/ccr3.5846.

Genetic characterization of the Albanian Gaucher disease patient population.

Cullufi P, Tabaku M, Velmishi V, Gjikopulli A, Tomori S, Dervishi E JIMD Rep. 2021; 57(1):52-57.

PMID: 33473340 PMC: 7802630. DOI: 10.1002/jmd2.12167.

The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.

Skrahina V, Gaber H, Vollstedt E, Forster T, Usnich T, Curado F Mov Disord. 2020; 36(4):1005-1010.

PMID: 33314351 PMC: 8246975. DOI: 10.1002/mds.28416.

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.

Revel-Vilk S, Fuller M, Zimran A Int J Mol Sci. 2020; 21(19).

PMID: 32998334 PMC: 7584006. DOI: 10.3390/ijms21197159.

References

Okano M . Recent Concise Viewpoints of Chronic Active Epstein-Barr Virus Infection. Curr Pediatr Rev. 2015; 11(1):5-9. DOI: 10.2174/1573396311666150501002809. View

Cox T . Biomarkers in lysosomal storage diseases: a review. Acta Paediatr Suppl. 2005; 94(447):39-42. DOI: 10.1111/j.1651-2227.2005.tb02109.x. View

Hurvitz N, Dinur T, Becker-Cohen M, Cozma C, Hovakimyan M, Oppermann S . Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease. Int J Mol Sci. 2019; 20(12). PMC: 6627663. DOI: 10.3390/ijms20123033. View

Reuser A, Verheijen F, Bali D, van Diggelen O, Germain D, Hwu W . The use of dried blood spot samples in the diagnosis of lysosomal storage disorders--current status and perspectives. Mol Genet Metab. 2011; 104(1-2):144-8. DOI: 10.1016/j.ymgme.2011.07.014. View

Rolfs A, Giese A, Grittner U, Mascher D, Elstein D, Zimran A . Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One. 2013; 8(11):e79732. PMC: 3835853. DOI: 10.1371/journal.pone.0079732. View

ORegan G, deSouza R, Balestrino R, Schapira A . Glucocerebrosidase Mutations in Parkinson Disease. J Parkinsons Dis. 2017; 7(3):411-422. DOI: 10.3233/JPD-171092. View

Hruska K, Lamarca M, Scott C, Sidransky E . Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008; 29(5):567-83. DOI: 10.1002/humu.20676. View

Elstein D, Mellgard B, Dinh Q, Lan L, Qiu Y, Cozma C . Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials. Mol Genet Metab. 2017; 122(1-2):113-120. DOI: 10.1016/j.ymgme.2017.08.005. View

Fairley C, Zimran A, Phillips M, Cizmarik M, Yee J, Weinreb N . Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. J Inherit Metab Dis. 2008; 31(6):738-44. DOI: 10.1007/s10545-008-0868-z. View

10.

Nalysnyk L, Rotella P, Simeone J, Hamed A, Weinreb N . Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2016; 22(2):65-73. DOI: 10.1080/10245332.2016.1240391. View

11.

den Dunnen J, Dalgleish R, Maglott D, Hart R, Greenblatt M, McGowan-Jordan J . HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016; 37(6):564-9. DOI: 10.1002/humu.22981. View

12.

Horowitz M, Zimran A . Mutations causing Gaucher disease. Hum Mutat. 1994; 3(1):1-11. DOI: 10.1002/humu.1380030102. View

13.

Smith L, Mullin S, Schapira A . Insights into the structural biology of Gaucher disease. Exp Neurol. 2017; 298(Pt B):180-190. DOI: 10.1016/j.expneurol.2017.09.010. View